Muutke küpsiste eelistusi

Plasma Cell Dyscrasias Softcover Reprint of the Original 1st 2016 ed. [Pehme köide]

Edited by , Edited by
  • Formaat: Paperback / softback, 361 pages, kõrgus x laius: 235x155 mm, kaal: 563 g, 7 Illustrations, color; 2 Illustrations, black and white; VI, 361 p. 9 illus., 7 illus. in color., 1 Paperback / softback
  • Sari: Cancer Treatment and Research 169
  • Ilmumisaeg: 16-Jun-2018
  • Kirjastus: Springer International Publishing AG
  • ISBN-10: 3319820788
  • ISBN-13: 9783319820781
Teised raamatud teemal:
  • Pehme köide
  • Hind: 104,29 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 122,69 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Paperback / softback, 361 pages, kõrgus x laius: 235x155 mm, kaal: 563 g, 7 Illustrations, color; 2 Illustrations, black and white; VI, 361 p. 9 illus., 7 illus. in color., 1 Paperback / softback
  • Sari: Cancer Treatment and Research 169
  • Ilmumisaeg: 16-Jun-2018
  • Kirjastus: Springer International Publishing AG
  • ISBN-10: 3319820788
  • ISBN-13: 9783319820781
Teised raamatud teemal:
This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites. The plasma cell dyscrasias investigated include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, plasmacytoma, immunoglobulin deposition diseases (primary amyloidosis and systemic light and heavy chain deposition diseases), and Waldenström’s macroglobulinemia. In the case of multiple myeloma, the coverage ranges from genomic aberrations and microRNAs to treatment for different patient groups, upcoming novel therapies, immunotherapy, and transplantation. The book reflects the significant research advances achieved in this field during the past few years, which have enhanced our understanding of the molecular mechanisms responsible for the pathogenesis of plasma cell dyscrasias.
MGUS and smoldering myeloma.- Multiple Myeloma.- Primary amyloidosis,
systemic light chain and heavy chain diseases plasmacytoma.- Waldenstroms
Macroglobulinemia.